CALADRIUS BIOSCIENCES, INC. Stock Agreements
13 Contracts & Agreements
- Series D Preferred Stock Purchase Agreement, dated April 26, 2022, among Caladrius Biosciences, Inc. and Cend Therapeutics Inc (Filed With SEC on April 27, 2022)
- Description of Capital Stock (Filed With SEC on February 25, 2021)
- Description of Capital Stock (Filed With SEC on March 5, 2020)
- Amendment No. 1 to Common Stock Sales Agreement, dated August 2, 2018, by and between Caladrius Biosciences, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 2, 2018)
- Common Stock Sales Agreement, dated February 8, 2018, by and between Caladrius Biosciences, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on February 8, 2018)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on November 5, 2015)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on May 6, 2015)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 13, 2014)
- AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 24, 2012)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on September 30, 2011)
- STOCK PURCHASE AND ASSIGNMENT AGREEMENT (Filed With SEC on May 17, 2011)
- WARRANTTO PURCHASE SHARES OF COMMON STOCK OF NEOSTEM,INC. (Filed With SEC on April 15, 2009)
- CERTIFICATEOF DESIGNATION of SERIESD CONVERTIBLE REDEEMABLE PREFERRED STOCK of NEOSTEM,INC. (Pursuantto Section 151(g) of the DelawareGeneral Corporation Law) (Filed With SEC on April 15, 2009)
